Inhibitory Effect of Disosium Cromoglycate and Ketotifen on Human Seminal Plasma-Induced Mast Cell Activation

BACKGROUND: Human seminal plasma (HSP)-induced hypersensitivity is one of the serious complications with sexual intercourse. The clinical manifestations of HSP-induced hypersensitivity may be related to the release of vasoactive mediators from mast cell induced by HSP. It has recently been reported that HSP modulates immune systems and induces mast cell degranulation and histamine release from rat peritoneal mast cells (RPMC). Ketotifen and disodium cromoglycate (DSCG), anti-asthmatic and anti-allergic drugs, have a role of mast cell stabilization and inhibit mast cell-induced leukocyte rolling and adhesion. But the inhibitory agents of HSP-induced mast cell activation are unknown. This study was performed to investigate the effects of DSCG and ketotifen on the HSP-induced mast cell activation. METHODS: For this, influences of DSCG and ketotifen on the human seminal plasma-induced degranulation, histamine release and morphological changes of RPMC were observed. RESULTS: The mast cell degranulation and histamine release of RPMC by HSP were induced in a dose-dependent fashion. The HSP-induced cytomorphological changes such as swelling, intracellular vacoules, and interrupted cell boundary were significantly inhibited by pretreatment with DSCG or ketotifen. DSCG and Ketotifen inhibited the HSP-induced degranulation and histamine release from RPMC. CONCLUSION: From the above results, it is suggested that DSCG and ketotifen have a inhibitory effect of the HSP-induced mast cell activation. DSCG and ketotifen may be used for treatment of HSP-induced hypersensitivity.

The difference of interieukin - 4 and interferon - r production of Der p I stimulated T cells and effects of immunomodulator in house dust mite sensitive atopic and non - atopic individuals / 천식및알레르기

BACKGROUND: Allergic diseases are characterized by immediate - and late - phase reactions to various allergens by the selective activation of a subset of CD4 + T cells. In response to allergen, T cells isolated from atopic donors are biased to low levels of IFN - y and high levels of IL - 4, and vice versa by T cells from non - atopic donor. Objective : The aim of this study was to evaluate the patterns of IL - 4 and IFN - y production after Der p I stimulation and the effect on the cytokine production from T cells by budesonide, disodium cromoglycate and cyclosporin A in atopic and non - atopic individuals. MATERIAL AND METHOD: Seven Der p I specific atopic and 7 non - atopic individuals were selected. We decided the 50% inhibiting concentration of each immunomodulator by lymphocyte proliferation assay, and measured their effects on the cytokine production in vitro by intracellular IL - 4, IFN - y staining and flow cytometry. Results and CONCLUSION: There was significant difference on stimulation index ( SI ) of production of IFN - y as well as IL-4 after Der p I stimulation between atopic and non-atopic individuals ( IL - 4 ; 1.57 +/- 0.7 : 0.98 +/- 0.2, p = 0.026, IFN - r : 1.45 +/- 0.5 : 0.95 +/- 0.2, p = 0.048 ). The synthesis of IL - 4, and IFN - r were significantly inhibited after the stimulation of every immunomodulators in atopic individuals, DSCG couldnt inhibit IL - 4 and IFN - r in nonatopic individuals. There was no significant difference in the inhibiting effect of these immunomodulators in both of them.

Therapeutic Predictor of Disodium Eromoglycate(DSCG) on Bronchial Asthma / 대한내과학회지

OBJECTIVES: Although DSCG protects against the stimuli of various bronchoconstictor, such as exercise, it is not effective to all patients. There seems to be no therapeutic predictor that determines effectiveness of DSCG on bronchial asthma. Although it is commonly assumed that children with predominantly allergic asthma have a better response to DSCG therapy than adult patient, this has not been convincingly demonstrated, and even adult with late onset nonallergic asthma may benefit. In this study, we evaluated the factors that potentially influenced the ability of DSCG to reduce bronchial hyperresponsibility. METHODS: The treatment groups were sub-divide into effective group(n=14) and ineffective group(n=6) on the basis of significant improvement of followedup PC20 after long term therapy of DSCG. We compared clinical and laboratory data and pulmonary function test between two groups. RESULTS: 1) Disease durtion and pre-treatment pulmonary function (FEV1% predicted, FVC% predicted value) may play a role in determining effectiveness of DSCG on bronchial asthma(p0.05). CONCLUSION: These results show that DSCG is effective in adult chronic asthma and early administration of DSCG, good pulmonary function test and allergic rhinitis history may lead to more favorable outcome.